Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

CAR-T Digest - August 2020

Weekly Digest - January 2026

20 January 2026: Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Eli Lilly announced that the U.S. FDA has granted Breakthrough Therapy designation to sofetabart mipitecan for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received bevacizumab and mirvetuximab soravtansine, where eligible
The designation underscores the high unmet need in platinum-resistant ovarian cancer, a setting associated with limited treatment options and poor outcomes and is intended to expedite development and regulatory review based on early signs of meaningful clinical benefit
The FDA’s decision is supported by encouraging preliminary results from a Phase 1a/b study, with data presented at ASCO 2025 and ESMO 2025 showing antitumor responses across all dose levels and across all levels of folate receptor alpha expression, including in patients who had progressed on prior mirvetuximab soravtansine
Early clinical findings also suggest a favorable tolerability profile, with low rates of interstitial lung disease, peripheral neuropathy, and alopecia, and no significant ocular toxicity observed to date, strengthening confidence in the therapy’s continued development
Building on these results, Lilly has initiated the global Phase 3 FRAmework-01 trial to further evaluate sofetabart mipitecan as monotherapy in platinum-resistant ovarian cancer and in combination with bevacizumab in platinum-sensitive disease, aiming to bring a new treatment option to patients with advanced ovarian cancer across all levels of folate receptor expression